LARIMAR THERAPEUTICS, INC.

Analyst Reco. Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
6.38 ^USD	-9.50%		-11.63%	+40.22%

Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ
Mar. 14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating	Feb. 13	MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating	Feb. 13	MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating	Feb. 13	MT
Citigroup Upgrades Larimar Therapeutics to Buy From Neutral, Price Target is $4.50	Nov. 17	MT
Citigroup Cuts Larimar Therapeutics' Price Target to $4.50 From $7, Maintains Neutral Rating	23-05-18	MT
Guggenheim Adjusts Larimar Therapeutics' Price Target to $14 From $12, Keeps Buy Rating	23-05-17	MT
Citigroup Initiates Larimar Therapeutics at Neutral Rating	22-12-13	MT
Guggenheim Starts Larimar Therapeutics at Buy With $12 Price Target	22-10-19	MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating	22-09-19	MT
William Blair Upgrades Larimar Therapeutics to Outperform From Market Perform	22-09-19	MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $8 From $30, Maintains Market Outperform Rating	22-02-16	MT
William Blair Downgrades Larimar Therapeutics to Market Perform From Outperform	22-02-15	MT
LARIMAR THERAPEUTICS : JMP Securities Adjusts Price Target on Larimar Therapeutics to $30 From $43, Maintains Market Outperform Rating	21-05-26	MT
LARIMAR THERAPEUTICS : JMP Securities Starts Larimar Therapeutics at Market Outperform with $35 Price Target	21-02-10	MT
LARIMAR THERAPEUTICS : William Blair Initiates Coverage on Larimar Therapeutics With Outperform Rating	21-02-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer